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Abstract
Background: Benign prostatic hyperplasia (BPH) is a prevalent entity in elderly men and transurethral resection of
the prostate (TURP) still represents the gold standard of surgical treatment despite its considerable perioperative
morbidity. Recently, prostatic artery embolization (PAE) was described as a novel effective and less invasive
treatment alternative. Despite promising first results, PAE still has to be considered experimental due to a lack of
good quality studies. Prospective randomized controlled trials comparing PAE with TUR-P are highly warranted.
Methods/design: This is a single-centre, prospective, randomized, non-inferiority trial comparing treatment effects and
adverse events of PAE and TURP in a tertiary referral centre. One hundred patients who are electable for both treatment
options are randomized to either PAE or TURP. Changes of the International Prostate Symptom Score (IPSS) after
3 months are defined as primary endpoint. Changes in bladder diaries, laboratory analyses, urodynamic investigations
and standardised questionnaires are assessed as secondary outcome measures. In addition contrast-enhanced
magnetic resonance imaging of the pelvis before and after the interventions will provide crucial information
regarding morphological changes and vascularisation of the prostate. Adverse events will be assessed on every
follow-up visit in both treatment arms according to the National Cancer Institute Common Terminology Criteria for
Adverse events and the Clavien classification.
Discussion: The aim of this study is to assess whether PAE represents a valid treatment alternative to TURP in
patients suffering from BPH in terms of efficacy and safety.
Trial registration: ClinicalTrials.gov NCT02054013.
Keywords: Prostate, Benign prostatic hyperplasia, Transurethral resection of the prostate, Embolization,
Prostatic artery embolization, Comparative clinical trial
Background
Benign prostatic hyperplasia (BPH) is a prevalent en-
tity, affecting over 50% of men older than 60 years [1].
The clinical picture of the disease includes lower urin-
ary tract symptoms such as interrupted and weak urin-
ary stream, nocturia, urgency and leaking and even
sexual dysfunction in some individuals [2]. Medical
therapy is usually the first-line treatment [3]. However,
the efficacy of drugs like alpha-blockers is limited, and
as disease progresses more invasive treatment options
have to be taken into consideration.
In cases with moderate to severe lower urinary tract
symptoms transurethral resection of the prostate (TURP)
is still the standard treatment. TURP, however, is limited
to prostates smaller than 60-80 ml and the procedure is
associated with a substantial complication rate. The cu-
mulative short-term morbidity rate is around 11% and
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the necessity for surgical revision is as high as 6%. Bleed-
ing requiring transfusions and transurethral resection
syndrome represent potentially serious threats to elderly
and frail patients [4]. Prostatic artery embolization (PAE)
has been suggested as a minimal invasive alternative pro-
cedure, which can be performed in an outpatient setting
with rapid recovery and low morbidity [5,6].
PAE was first described in 1979 by Lang et al. [7] as a
treatment option in intractable prostatogenic haemor-
rhage and emerged as a safe and effective treatment
thanks to technical refinements throughout the last de-
cades. Using PAE in this purpose, DeMeritt et al. were
the first to report on relief of BPH-related bladder out-
let obstruction after transarterial polyvinyl alcohol
prostate embolization in 2000 [8].
First intentional treatment of BPH by PAE was pub-
lished in 2008 [9]. Subsequently, promising short- and
medium-term results could be shown for patients with
symptomatic BPH, refractory to medical treatment: A
significant improvement in the International Prostate
Symptom Score (IPSS) and maximum urinary flow
rate, as well as a reduction of prostate volume and
post-void residual urine were reported in several stud-
ies [10-13]. Methods and technique to perform PAE
are well established and have been described in several
publications [14,15]. PAE was shown to be a safe
procedure with low morbidity in carefully selected
patients [16,17].
However, data concerning PAE has been criticized for
different reasons: There is just a small number of studies
published by only three research groups with an unclear
overlap of the patients that were described so far. More-
over, quality of the studies available was referred to be
poor due to study type (cohort), unclear patient selec-
tions and dropouts as well as statistical limitations and
missing long-term results [17].
Currently, only a single trial was published compar-
ing TURP and PAE: Gao et al. report on promising
results of PAE with a post-interventional course out-
shining the data published so far [18]. This study, how-
ever, was devoted little attention most likely due to
ambiguities regarding patient selection and good clin-
ical practice issues. TURP still remains clearly the gold
standard in surgical treatment of BPH and a prospect-
ive randomized trial according to good clinical practice
(GCP) comparing PAE and TURP is mandatory, to
assess efficacy and safety of PAE in the treatment of
BPH.
Methods and design
Study design and location
This is a prospective, randomized, non-inferiority trial
conducted at the urological and radiological departments
of Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Study population and recruitment
Recruitment of the study participants is performed at
the urological outpatient clinic of Cantonal Hospital St.
Gallen by the principle investigator (PI). The PI will
check for inclusion and exclusion criteria (Table 1) by
reviewing the patient’s medical record and by patient-
doctor conversation. Study participants are thoroughly
informed about the study by the study physician. Pos-
sible questions are answered by the PI. If the patient
feels well informed and confident to participate in the
trial, informed consent can be given within the consult-
ation. If the patient needs further time for consideration,
an additional appointment in the outpatient clinic will
be arranged within the next 2–3 weeks. Anyway, the pa-
tient has got at least 2–3 weeks till admission to the hos-
pital to get clear on study participation and is able to ask
further questions at the day of admission.
Study randomisation
Randomisation will be performed using SecuTrial (Inter-
Active Systems GmbH, Berlin, Germany) stratifying on age
(<70, ≥70 years) and prostate volume (<50 ml, ≥50 ml).
Study procedures
After baseline visit participants are randomized to TURP
or embolisation (Figure 1). Both interventions are per-
formed in an inpatient setting. All subjects receive peri-
operative antibiotic prophylaxis started one day before
procedure and continued for one day after catheter re-
moval (Ciprofloxacin 500 mg twice daily, except infec-
tion with different resistance profile was proved before).
Moreover, anti-inflammatory (Diclofenac 75 mg twice
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Men older than 40 • Severe atherosclerosis
• Patient must be a candidate for
TURP
• Severe tortuosity in the aortic
bifurcation or internal iliac arteries
• Refractory to medical therapy or
patient is not willing to consider
(further) medical treatment
• Acontractile detrusor
• Patient has a prostate size of at
least 25 ml and not more than
80 ml, measured by ultrasound
• Neurogenic lower urinary tract
dysfunction
• IPSS ≥8 • Urethral stenosis
• QoL ≥3 • Bladder diverticulum
• Qmax < 12 and/or urinary
retention
• Bladder stone with surgical
indication
• Written informed consent • Allergy to intravenous contrast
media
• Contraindication for MRI imaging
• Preinterventionally proven
adenocarcinoma of the prostate
• Renal failure (GFR < 60 ml/min)
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daily) and acid-suppressing medication (Pantoprazole
40 mg once daily) is administered for 1 week starting at
the day of intervention. Prostatic medication is aban-
doned at the day of TURP and 2 weeks after PAE (due
to supposed slower efficacy).
TURP
For monopolar transurethral resection, a 24 F Storz resec-
toscope with a cutting power of 150 W and a coagulation
power of 60 W is used. A standard tungsten wire loop
(Karl Storz Endoskope; Anklin AG, Binnigen, Switzerland)
and electrolyte-free mannitol-sorbitol solution (Purisole,
Fresenius Kabi AG, Bad Homburg, Germany) will be used
for TURP. Surgery will be performed under spinal or gen-
eral anaesthesia according to patient’s and anaesthetist’s
preferences by one of the physicians involved into the
study (LM, DA, HPS, DSE). A 20 F three-way catheter is
inserted for irrigation after resection and left for at least
two days depending on bleeding tendency.
PAE
A 16 F transurethral catheter is inserted prior to inter-
vention for better radiological orientation. After local
anaesthesia, a unilateral femoral sheath is placed (normally
the right common femoral artery) and the patient will
have a selective internal iliac arteriogram of the anterior
division of both internal iliac arteries by a 5 F catheter to
identify the prostatic arterial supply. In special anatomical
variants, arteriograms of the external iliac and their
branches will be performed. The prostatic vessels, which
can derive from every branch of the anterior division, will
be selectively catheterized with a 2–3 F micro catheter
and subsequent embolization will be performed with 250-
400 μm sized Embozene Microspheres (Celonova, San
Antonio, TX). The embolization endpoint will be absence
of perfusion of the prostate on post embolization angiog-
raphy and stasis of flow in the prostate arteries. This pro-
cedure is performed on both sides whenever possible.
Embolization will only be performed by a single interven-
tional radiologist (LH). Transurethral catheter is removed
on the first morning after intervention.
Study outcome measures
Characteristics and timing of visits
Regular follow-up controls starting one week after inter-
vention and continued up to 5 years will be performed,
assessing the parameters described in Figure 1.
Primary and secondary endpoints
Change of International Prostate Symptom Score (IPSS)
3 months after intervention was defined as primary end-
point. Secondary study endpoints are shown in Table 2.
Statistics, study sample size and power calculation
For the primary endpoint, changes in IPSS at 12 weeks
will be compared using a one-sided t-test with signifi-
cance level 0.025 (equivalent to using the boundaries
from a 95% confidence interval (CI)). As long as the t-
test is not significant (that is, the 95% CI is entirely
above −3), PAE will be considered non-inferior to TUR-
P. A second analysis of the primary endpoint will be ad-
justed for IPSS at baseline (using linear regression), and
Figure 1 Timetable and characteristics of study visits.
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therefore an adjusted confidence interval will also be
reported.
Mean differences and corresponding 95% CI will be re-
ported for all secondary endpoints, as well as the p-value
from a one-sided t-test. Where an endpoint is clearly not
normally distributed, results from a one-sided Mann–
Whitney U-test will be substituted. Changes over time
will be compared pairwise in the same fashion.
In a study performed at our own institute [19], the stand-
ard deviation for IPSS was 4.6. A one-sided t-test with one-
sided significance level 0.025 will have 80% power to reject
the null hypothesis that the two treatments are not equiva-
lent (that is, the difference in means is −3 or further from
zero in the same direction), assuming the expected differ-
ence is 0 and the common standard deviation is 4.6, when
the sample size is 38 patients in each group. Assuming a
dropout rate of 20%, we aim to recruit 100 patients total.
Regulatory issues
Ethical approval
Study was approved by the local ethics committees
(EKSG 14/004) and is performed in consideration of the
World Medical Association Declaration of Helsinki [20],
the guidelines for GCP [21], and the guidelines of the
Swiss Academy of Medical Sciences [22]. Handling of all
personal data will strictly comply with the federal law of
data protection in Switzerland [23].
Quality control, quality assurance and confidentiality
An expert of Clinical Trials Unit (CTU) St. Gallen con-
ducts data monitoring according to GCP. Trial-related
monitoring, audits and regulatory inspections from the
ethics committee (EKSG) will be permitted by the princi-
pal investigator, providing direct access to source docu-
ments. Data collection is performed using electronic case
report forms (SecuTrial) programmed by CTU St. Gallen.
The respect of the professional secrecy is guaranteed.
Insight into the data collected in this trial will only be pro-
vided to the involved investigators, the members of the
ethics committee experts responsible for the monitoring.
Missing data
Patients will be included in the primary analysis of the
primary endpoint, provided that baseline and 12 week
IPSS measurements are available. For all other analyses,
all collected data will be analyzed.
Safety
All adverse events (AE) and serious adverse events (SAE)
which might be related to the study procedures are col-
lected, fully investigated and documented during the en-
tire study period. Assessment of severity of all AEs will
be performed according to National Cancer Institute
Common Terminology Criteria for Adverse Events v4.0
(CTCAE) and according to the Clavien classification [24].
All SAEs related to study intervention, are reported to
the local Ethics Committee. All AEs and SAEs will be
followed as long as medically indicated.
Discussion
The aim of this study is to assess whether PAE is a valu-
able treatment option compared to TURP in patients with
BPH, assessing both, short- and long-term treatment ef-
fects as well as complications. Using a prospective, ran-
domized, non-inferiority trial design with clearly defined
endpoints, as well as inclusion and exclusion criteria and
performed according to well-defined quality standards,
data will help to estimate treatment efficiency of PAE bet-
ter. Moreover, potential advantages as well as problems of
this emerging intervention can be analysed. The study
might also help to define patients that are particularly suit-
able for PAE and patients that should be treated alterna-
tively. In addition, magnetic resonance imaging performed
at different time intervals to intervention might help to
get a better understanding of the underlying mechanisms.
Trial status
The trial is in the recruiting phase at the time of manu-
script submission.
Abbreviations
BPH: Benign prostate hyperplasia; CI: Confidence interval; GCP: Good clinical
practice; IIEF: International index of erectile function; IPSS: International
prostate symptom score; MRI: Magnetic resonance imaging; NIH-
CPSI: National institute of health – chronic prostatitis symptoms score;
PAE: Prostatic artery embolization; PI: Principle investigator; PSA: Prostate
Table 2 Primary and secondary endpoints
Primary endpoint • Changes in the IPSS 12 weeks after
intervention
Secondary endpoints
(see Figure 1 for time points)
• Changes in free uroflowmetry and
post-void residual
• Changes in bladder diary
• Changes in urodynamic investigation
• Changes in IPSS, CPSI and IIEF
• Changes of haemoglobin and serum
PSA
• Duration of post procedure
catheterisation and hospitalisation
• Procedure time and radiation
parameters
• Changes of prostate volume, measure
of devascularized/resected tissue using
MRI
• Comparison of prostate size, measured
preoperatively by TRUS and MRI at
baseline
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specific antigen; TURP: Transurethral resection of the prostate;
TRUS: Transrectal ultrasound.
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